Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

In trials, in 708 women, when combined with hormone therapy, the drug doubled the time the cancer took to grow, from 3.6 ...

Cancer treatments like chemotherapy can lead to extensive hair loss. While hair may start regrowing 4 to 6 weeks after the treatment is over, it also differs from before in texture and colour. After ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Drug rashes can be an unwanted side effect of many medications. Learn which medications can cause these skin reactions.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

Can a robot help prepare cancer medication in a hospital pharmacy? That's what hospital pharmacist Tjerk Geersing ...

On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer pre-chemotherapy. Just six days ...

Modern cancer treatments have evolved beyond traditional chemotherapy to include targeted approaches such as immunotherapy, ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

To advance this research towards commercialization, Daniel Fologea benefits from an NSF Transform grant for marketed oriented ...